semaglutide patent india Ozempic Ends On March 20 And A Generic Deluge Is Coming Forcing Prices To Fall Semaglutide hits its patent cliff

Published Phase 2 trial data (NEJM, 2023) demonstrated substantial reductions in body weight in some participants exceeding 20% over approximately 48 weeks making retatrutide one of the most potent agents currently in development for obesity and metabolic disease

Its unique mechanism of action, mimicking GLP-1, sets it apart from traditional methods

Because retatrutide is still in clinical development, the full profile of its effects on sleep continues to be characterised, and any causal relationship between the drug and insomnia has not yet been formally established

Safe Alternatives: PlexusDx Personalized GLP-1 Strategies PlexusDx offers multiple compounded GLP-1 formulations designed to maximize weight loss efficacy without complex multi-agent combinations